Skip to main content

Israeli pharmaceutical company Teva receives Chinese approval for new Huntington's treatment

The approval to provide the tablets in China that treat the deadly neurological disease is the second in the world after the United States.
The logo of Teva Pharmaceutical Industries is seen during a news conference hold by its CEO, Kare Schultz, to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen - RC16F0E05360

A major Israel-American pharmaceutical company can now sell its medication for treating Huntington’s disease in China. 

Teva Pharmaceuticals received approval from China’s National Medical Products Administration for its Austedo tablets that treat the deadly neurological disease, the company said in a press release today. China is only the second country to approve the use and sale of the Huntington’s medication, Teva Pharmaceuticals said. The other country is the United States.

Access the Middle East news and analysis you can trust

Join our community of Middle East readers to experience all of Al-Monitor, including 24/7 news, analyses, memos, reports and newsletters.


Only $100 per year.